Lundbeck and Takeda form alliance to develop and commercialize a portfolio of novel compounds in the US and Japan for the treatment of mood and anxiety disorders

H. Lundbeck A/S and Takeda Pharmaceutical Company Limited today
announced a strategic alliance for the exclusive co-development and
co-commercialization in the United States and Japan of several
compounds in Lundbeck's pipeline for the treatment of mood and
anxiety disorders.

The partnership will initially focus on co-development and
co-commercialization of the two most advanced compounds in Lundbeck's
pipeline for mood and anxiety disorders, Lu AA21004 and Lu AA24530,
with an option under certain conditions to include two other
compounds of the same class in earlier stages of development.
Assuming approvals, the companies plan to co-promote the compounds in
the United States and Japan.

Under the terms of the agreement, Lundbeck will receive an initial
payment of USD 40 million and potentially a maximum of USD 345
million in additional development milestone payments. Takeda and
Lundbeck will jointly complete the development programmes, with
Takeda booking the total sales and funding the majority of the
remaining development activities. Lundbeck will receive a share of
the revenue generated in the US and Japan as well as royalty payments
on Takeda's share of revenues. Other economic conditions are not
disclosed."We are delighted to have reached an agreement with one of the
strongest global players in central nervous system research," says
Yasuchika Hasegawa, president of Takeda. "Lundbeck has a novel
compounds portfolio for the treatment of mood and anxiety disorder
and we believe those compounds have the potential to demonstrate
substantial benefits compared to existing therapies and that they
will therefore be able to target unmet patient needs, while
contributing to the enhancement of our CNS franchise which is one of
our core therapeutic areas.""Takeda's experience in building up a leading and one of the fastest
growing companies in the US combined with its market leader position
in Japan has made us confident that we have identified a fully
committed and highly competent partner for our portfolio of compounds
for the treatment of mood and anxiety disorders," said Dr. Claus
Braestrup, president and CEO of Lundbeck. "This agreement also
provides a unique opportunity for Lundbeck to build a commercial
presence both in the US and in Japan with the support of a strong
partner, while we continue to utilize our own European and
international platform outside the US and Japan to commercialize the
compounds."

About the compounds
The compounds belong to a new chemical class that has been discovered
at Lundbeck. Compared with currently approved antidepressants,
preclinical models have demonstrated that the compounds have the
potential to address important unmet needs for patients in terms of
both fast onset of effect and increased efficacy. The most advanced
compound, Lu AA21004, is currently in clinical phase II development
for the treatment of major depressive disorder (MDD). It is expected
that the clinical trials will be finalized, opened and announced
later this year.

H. Lundbeck A/S forward-looking statement
Lundbeck will receive USD 40 million as an extraordinary initial
payment, which will positively influence the Lundbeck Group's revenue
for 2007.

Lundbeck forecasts strong growth in consolidated profit for 2007
relative to 2006. Excluding extraordinary items, Lundbeck expects a
profit from operations of more than DKK 2.5 billion, an EBIT margin
of 25% and a level of investment of approximately DKK 650 million.

Takeda contacts


Investors & Media:

Seizo Masuda
Coordinator, Corporate Communications Dept.
+81-3-3278-2037


Lundbeck contacts


Investors:                   Media:

Jacob Tolstrup               Caroline Broge
Director, Investor Relations Media Relations Manager
+45 36 43 30 79              +45 36 43 26 38
+1 201 350 0187



                      ________________________

Stock Exchange Release No 292 - 5 September 2007

About Takeda
Located in Osaka, Japan, Takeda (TSE:4502) is a research-based global
company with its main focus on pharmaceuticals. As the largest
pharmaceutical company in Japan and one of the global leaders of the
industry, Takeda is committed to striving toward better health for
individuals and progress in medicine by developing superior
pharmaceutical products. Additional information about Takeda is
available through its corporate website, www.takeda.com.

About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2006,
the company's revenue was DKK 9.2 billion (approximately EUR 1.2
billion or USD 1.6 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com